• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Dec 17;16(1):11176.
doi: 10.1038/s41467-025-66136-6. Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection

Zhenyu Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Isabel Uribe[SUP] #[/SUP][SUP] 2 [/SUP], Kaitlin A Davis[SUP] 1 [/SUP], Robert L McPherson[SUP] 2 [/SUP], Gloria P Larson[SUP] 1 [/SUP], Mohsen Badiee[SUP] 2 [/SUP], Vy Tran[SUP] 1 [/SUP], Mitchell P Ledwith[SUP] 1 [/SUP], Elizabeth M Feltman[SUP] 1 [/SUP], Shuǐqìng Yú[SUP] 3 [/SUP], Yíngyún Caì[SUP] 3 [/SUP], Che-Yuan Chang[SUP] 2 [/SUP], Xingyi Yang[SUP] 2 [/SUP], Zhuo Ma[SUP] 2 [/SUP], Paul Chang[SUP] 4 5 6 [/SUP], Jens H Kuhn[SUP] 3 [/SUP], Anthony K L Leung[SUP] 7 8 9 10 [/SUP], Andrew Mehle[SUP] 11 [/SUP]



Affiliations
Abstract

ADP-ribosylation is a highly dynamic and fully reversible post-translational modification performed by PARP enzymes that modulates protein function, abundance, localization, and turnover. Here we show that PARPs mount an antiviral response to influenza A virus infection causing a rapid and dramatic upregulation of global ADP-ribosylation that inhibits viral replication. Mass spectrometry analyzes define the global ADP-ribosylome during infection, creating an infection-specific profile with almost 4000 modification sites on ~1000 host proteins, as well as over 100 modification sites on viral proteins. Our data suggest that the global increase reflects a change in the form of ADP-ribosylation rather than modification of new targets. Functional assays demonstrate that modification of the viral replication machinery antagonizes its activity. We further show that the influenza A virus protein NS1 counteracts the anti-viral activity of PARPs and ADP-ribosylation, assigning a new activity to the primary viral antagonist of innate immunity. We identify PARP1 as the enzyme producing the majority of poly(ADP-ribose) present during infection. Influenza A virus replicates faster in cells lacking PARP1, linking PARP1 and ADP-ribosylation to the anti-viral phenotype. Together, these data establish ADP-ribosylation as an anti-viral innate immune-like response to viral infection antagonized by a previously unknown activity of NS1.


 
Back
Top